Xiangbin Zhang

Neuroprotection in the early window: a randomized controlled trial of butylphthalide initiation within 3 hours in acute ischemic stroke

Neuroprotective agents have shown promise in preclinical studies but failed to demonstrate efficacy in clinical trials, potentially due to delayed treatment initiation. The optimal therapeutic window for neuroprotection in acute ischemic stroke (AIS) remains undefined. We aimed t...